Bumpus Namandje
SEC insider (Form 3/4/5 filer). CIK 0002060594. Director at RECURSION PHARMACEUTICALS, INC. (RXRX). 5 reported Form 4/5 transactions since Sep 2024; latest on Jun 18, 2026. Located in SALT LAKE CITY, UT.
Companies Bumpus Namandje has filed insider reports for
- RECURSION PHARMACEUTICALS, INC. (RXRX): Director
Bumpus Namandje
CIK: 0002060594
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)2 (40.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (60.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
RXRX
RECURSION PHARMACEUTICALS, INC.
Director
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 18, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
SaleDirect4K shares at avg. $3.18$13K - Jun 17, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
AwardDirect88.4K shares- - Jun 3, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
SaleDirect4.4K shares at avg. $3.54$16K - Jun 18, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
AwardDirect11K shares- - Mar 17, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
AwardDirect36.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 18, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale | 3,963 | $3.18 | $12,602 | Direct |
| Jun 17, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Award | 88,424 | - | $0 | Direct |
| Jun 3, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale | 4,386 | $3.54 | $15,526 | Direct |
| Jun 18, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Award | 11,008 | - | - | Direct |
| Mar 17, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Award | 36,549 | - | - | Direct |
1-5 of 5 transactions